Skip to main content

Table 3 Expression of biomarkers and HER2 gene status in BTC samples from patients.

From: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Sample EGFR TGF-α P-MAPK P-AKT PTEN HER2 HER2 FISH *
1 0 0 - - 1+ 0 ND
2 3+ + - - 1+ 0 ND
3 3+ + - - 1+ 0 ND
4 3+ + - + 3+ 0 ND
5 3+ + - - ND 1+ ND
6 3+ + - - 1+ 0 ND
7 3+ + - + 2+ 0 ND
8 3+ +++ - + 3+ 0 ND
9 3+ 0 - - 1+ 0 ND
10 3+ 0 + + 2+ 0 ND
11 3+ +++ + + 3+ 1+ ND
12 0 0 - - ND ND ND
13 2+ + + + 2+ 0 ND
14 3+ + + - 2+ 3+ RATIO: 10
15 2+ + - - 1+ 2+ 1.4 POLYSOMY 17
16 1+ 0 - - 1+ 0 ND
17 0 0 - - 1+ 2+ 1.7 POLYSOMY 17
18 2+ + - + 1+ 0 ND
19 0 0 + + ND 2+ RATIO: 5.9
20 0 0 ND ND 3+ 0 ND
21 1+ ++ + + 3+ ND ND
22 0 0 - - 3+ 0 ND
23 0 0 - + 3+ 0 ND
24 1+ +++ + + 3+ 0 ND
25 3+ + + + 1+ 0 ND
26 0 0 - + 3+ 0 ND
27 0 0 + - 3+ ND ND
28 0 0 - - 3+ 0 ND
29 0 + + - 2+ 0 ND
30 0 + - + 1+ 3+ RATIO: 6.9
31 3+ 0 + + 3+ ND ND
32 0 ND + - 2+ 0 ND
33 3+ 0 + + 3+ 0 ND
34 3+ + - + 3+ 0 ND
35 3+ + + + 2+ ND ND
36 3+ + + + 3+ ND ND
37 3+ +++ + + 2+ ND ND
38 1+ ++ ND ND 2+ 0 ND
39 3+ + + + ND 0 ND
40 0 0 + + ND 0 ND
41 2+ + ND ND 2+ ND ND
42 3+ + ND ND 3+ 0 ND
43 0 0 - - 3+ 0 ND
44 0 0 + - 2+ 0 ND
45 3+ + + + 1+ 0 ND
46 3+ + - + 3+ 0 ND
47 2+ ++ + + 1+ ND ND
48 2+ + + + 1+ ND ND
49 0 0 - - 3+ 0 ND
  1. ND: not determined,* HER2 FISH analysed as described in the "methods" section